Amgen Inc.

AMGN-Q

NASDAQ:AMGN

251.38
1.07 (0.43%)
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Located in the Conejo Valley, Amgen is the world's largest independent biotechnology firm.
More at Wikipedia

Analysis and Opinions about AMGN-Q

Signal
Opinion
Expert
Chart
WAIT
WAIT
March 1, 2021
It has been under-performing the overall market. Biotechs don't do well at this point seasonally. Its seasonal period starts in June and the trade could setup quite well. Don't look at it at this time.
Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
March 1, 2021
It has been under-performing the overall market. Biotechs don't do well at this point seasonally. Its seasonal period starts in June and the trade could setup quite well. Don't look at it at this time.
Brooke Thackray
Price
$226.900
Owned
Unknown
TOP PICK
TOP PICK
November 3, 2020

Stockchase Research Editor: Michael O'Reilly AMGN just released earnings and the 12% increase in revenues and 5% increase in EPS were likely held back due to government mandates to focus health spending towards COVID-19 projects. The company is now benefitting from the release of new arthritis and metastatic colorectal cancer treatments. They also signed a deal to partner with Eli Lilly to manufacture a coronavirus antibody treatment, when it is ready. They pay a good dividend, backed by a 50% payout ratio. We would trade this with a stop-loss of $205 and a target of of $255 -- over 15% upside. Yield 2.91% (Analysts’ price target is $254.12)

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
November 3, 2020

Stockchase Research Editor: Michael O'Reilly AMGN just released earnings and the 12% increase in revenues and 5% increase in EPS were likely held back due to government mandates to focus health spending towards COVID-19 projects. The company is now benefitting from the release of new arthritis and metastatic colorectal cancer treatments. They also signed a deal to partner with Eli Lilly to manufacture a coronavirus antibody treatment, when it is ready. They pay a good dividend, backed by a 50% payout ratio. We would trade this with a stop-loss of $205 and a target of of $255 -- over 15% upside. Yield 2.91% (Analysts’ price target is $254.12)

Stockchase Research
Price
$218.950
Owned
_N/A
WATCH
WATCH
October 20, 2020
A pure biotech company with a strong biosimilar business with a great core franchise in immunology. Their oncology business is also robust. They had a recent miss in one of their trials, which was the second miss this year. (There is another phase 3 trial this year.) He wants to see either more execution on their R&D drugs or backfill through some M&A in coming years. He's closely watching this.
Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
October 20, 2020
A pure biotech company with a strong biosimilar business with a great core franchise in immunology. Their oncology business is also robust. They had a recent miss in one of their trials, which was the second miss this year. (There is another phase 3 trial this year.) He wants to see either more execution on their R&D drugs or backfill through some M&A in coming years. He's closely watching this.
Paul MacDonald
Price
$232.540
Owned
No
BUY
BUY
September 29, 2020
It has a lot of irons in the fire including an oncology franchise they're not getting any credit for.
Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
September 29, 2020
It has a lot of irons in the fire including an oncology franchise they're not getting any credit for.
Jim Cramer - Mad Money
Price
$248.300
Owned
Unknown
HOLD
HOLD
September 18, 2019
The biotech grandddaddy. A great company that's produced some fine drugs, but other technologies have taken the shine off this stock. New drugs haven't driven the stock up. It does trade at a reasonable 11x earnings. A decent stock and it's stable, but lacks the punch of its peers. It depends what happens in the US election in Nov. 2020 too.
Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
September 18, 2019
The biotech grandddaddy. A great company that's produced some fine drugs, but other technologies have taken the shine off this stock. New drugs haven't driven the stock up. It does trade at a reasonable 11x earnings. A decent stock and it's stable, but lacks the punch of its peers. It depends what happens in the US election in Nov. 2020 too.
Gordon Reid
Price
$195.040
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
July 17, 2019
(A Top Pick Jul 05/18, Up 3%) One of the world's largest biotech companies. They have 3-4 blockbuster drugs in the pipeline in phase 1 & 2. It's an under-owned stock. Enbrel, their largest-selling drug, is undergoing a parent review. If Amgen wins--which he thinks will happen--then there'll be a 12% stock boost; if not, it will fall 12%. Either way, after this review, Amgen is still worth buying.
Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
July 17, 2019
(A Top Pick Jul 05/18, Up 3%) One of the world's largest biotech companies. They have 3-4 blockbuster drugs in the pipeline in phase 1 & 2. It's an under-owned stock. Enbrel, their largest-selling drug, is undergoing a parent review. If Amgen wins--which he thinks will happen--then there'll be a 12% stock boost; if not, it will fall 12%. Either way, after this review, Amgen is still worth buying.
Paul MacDonald
Price
$177.060
Owned
Yes
PARTIAL SELL
PARTIAL SELL
July 9, 2019
It has a nice head and shoulders, with a double-top at $210. It's now at a shoulder around $180. It needs to rise above this level. Continue to hold it or sell.
Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
July 9, 2019
It has a nice head and shoulders, with a double-top at $210. It's now at a shoulder around $180. It needs to rise above this level. Continue to hold it or sell.
Elliott Fishman
Price
$181.590
Owned
Unknown
COMMENT
COMMENT
May 23, 2019
Great product but the are matured. he prefers other Health Care names.
Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
May 23, 2019
Great product but the are matured. he prefers other Health Care names.
Bruce Murray
Price
$172.110
Owned
No
TOP PICK
TOP PICK
May 3, 2019
Large cap diversified biotech company. Seeing shorts because of a patent dispute. Diversified pipeline of drugs. Valuation is attractive. Buy this as a basket. Yield is 3.27%. (Analysts’ price target is $206.95)
Show full opinionHide full opinion
Large cap diversified biotech company. Seeing shorts because of a patent dispute. Diversified pipeline of drugs. Valuation is attractive. Buy this as a basket. Yield is 3.27%. (Analysts’ price target is $206.95)
Paul MacDonald
Price
$177.310
Owned
Yes
WAIT
WAIT
April 30, 2019
It's been in a choppy uptrend since 2017, and is now consolidating. Lows are around $180 and now testing that area. If it breaks out, it would be positive. Otherwise, it's wait and see.
Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
April 30, 2019
It's been in a choppy uptrend since 2017, and is now consolidating. Lows are around $180 and now testing that area. If it breaks out, it would be positive. Otherwise, it's wait and see.
Keith Richards
Price
$179.320
Owned
Unknown
DON'T BUY
DON'T BUY
April 22, 2019
The grandaddy of the biotechs, a good solid holding, trading at 14x earnings. But it lacks a catalyst.
Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
April 22, 2019
The grandaddy of the biotechs, a good solid holding, trading at 14x earnings. But it lacks a catalyst.
Gordon Reid
Price
$176.360
Owned
No
PAST TOP PICK
PAST TOP PICK
December 3, 2018
(A Top Pick Jul 05/18, Up 10%) He held onto this over the summer, despite expecting autumnal volatility. It's a diversified biotech and big in bio-similars, so AMGN would benefit from an uptick here. It's reasonably priced.
Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
December 3, 2018
(A Top Pick Jul 05/18, Up 10%) He held onto this over the summer, despite expecting autumnal volatility. It's a diversified biotech and big in bio-similars, so AMGN would benefit from an uptick here. It's reasonably priced.
Paul MacDonald
Price
$202.930
Owned
Yes
WAIT
WAIT
October 19, 2018

Had owned it for a number of years but sold it recently. The growth trajectory going forward was slowing. Still pretty cheap and great cash flow. For him to get back into this stock, it would have to be significantly lower.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
October 19, 2018

Had owned it for a number of years but sold it recently. The growth trajectory going forward was slowing. Still pretty cheap and great cash flow. For him to get back into this stock, it would have to be significantly lower.

Bryden Teich
Price
$201.800
Owned
No
TOP PICK
TOP PICK
July 5, 2018

One of the leading biotech firms. They have a number of new drugs that came out. Dividend yield of 2.8%. Market cap of $124 billion. (Analysts’ price target is $196.95)

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
July 5, 2018

One of the leading biotech firms. They have a number of new drugs that came out. Dividend yield of 2.8%. Market cap of $124 billion. (Analysts’ price target is $196.95)

Paul MacDonald
Price
$187.360
Owned
Yes
COMMENT
COMMENT
November 2, 2017

Pharmaceutical stocks have had a much more difficult time because of the presidential election, a time when they usually fall. However, they've bounced back as much as they normally do. This is not expensive. Trading at about 14X earnings and pays a nice dividend yield. Has some really great drugs in their pipeline. It continues to outperform on an earnings basis. He really likes this.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
November 2, 2017

Pharmaceutical stocks have had a much more difficult time because of the presidential election, a time when they usually fall. However, they've bounced back as much as they normally do. This is not expensive. Trading at about 14X earnings and pays a nice dividend yield. Has some really great drugs in their pipeline. It continues to outperform on an earnings basis. He really likes this.

Paul Harris, CFA
Price
$172.410
Owned
Yes
Showing 1 to 15 of 106 entries

Amgen Inc.(AMGN-Q) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 1

Stockchase rating for Amgen Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Amgen Inc.(AMGN-Q) Frequently Asked Questions

What is Amgen Inc. stock symbol?

Amgen Inc. is a American stock, trading under the symbol AMGN-Q on the NASDAQ (AMGN). It is usually referred to as NASDAQ:AMGN or AMGN-Q

Is Amgen Inc. a buy or a sell?

In the last year, 1 stock analyst published opinions about AMGN-Q. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is WAIT. Read the latest stock experts' ratings for Amgen Inc..

Is Amgen Inc. a good investment or a top pick?

Amgen Inc. was recommended as a Top Pick by Brooke Thackray on 2021-03-01. Read the latest stock experts ratings for Amgen Inc..

Why is Amgen Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Amgen Inc. worth watching?

1 stock analyst on Stockchase covered Amgen Inc. In the last year. It is a trending stock that is worth watching.

What is Amgen Inc. stock price?

On 2021-05-14, Amgen Inc. (AMGN-Q) stock closed at a price of $251.38.